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Abstract
Background: Induction of labor (IOL) is a common practice in many parts of the world. However, the benefits and
risks of preventive IOL for the mother and baby have yet to be critically assessed. This study is to investigate the effects
of preventive IOL for non-urgent indications at term on maternal and neonatal outcomes.
Methods: In this study, we applied a propensity score model to mimic a randomized clinical trial. Maternal and
neonatal outcomes were compared between women with preventive IOL at 37–39 weeks of gestation and women
with ongoing pregnancy (expectant management). The subjects were from the Consortium on Safe Labor, a study of
over 200,000 births from 19 hospitals across the US from 2002 to 2008.
Results: Both nulliparous and multiparous women induced preventively for non-urgent indications at 37–38 weeks’
gestation had lower rates of cesarean delivery compared to those delivered at later gestational weeks. However,
preventive IOL was associated with increased risks of adverse neonatal outcomes (adjusted odds ratio [aOR] = 1.68, 95 %
confidence interval [CI], 0.97–2.92 for nulliparas; aOR = 2.22, 1.32–3.74 for multiparas) and admission to NICU (aOR = 1.48,
0.99–2.20 for nulliparas; aOR = 2.08, 1.47–2.96 for multiparas) at 37 weeks’ gestation. A longer maternal hospital stay was
found among all women with preventive IOL.
Conclusions: Preventive IOL for non-urgent indications may be associated with a decreased risk of cesarean delivery at
early term but increased risks of adverse neonatal outcomes at 37 weeks. It also results in a longer hospital stay than
expectant management.
Keywords: Preventive induction of labor, Propensity score model, Cesarean delivery, Maternal outcomes, Neonatal
outcomes
Background
Induction of labor is a common practice in many parts of
the world [1]. More recently, “preventive (or proactive)
induction” for women who have certain risk factors or non-
urgent conditions for potentially unfavorable perinatal out-
comes has been advocated [2, 3]. A Cochrane review [4]
showed that planned early delivery versus expectant manage-
ment for a suspected compromised fetus at term did not
result in any differences in major outcomes of perinatal mor-
tality, significant neonatal or maternal morbidity or neurode-
velopmental disability. Nonetheless, the authors cautioned
that the review was based on only one large trial and two
smaller trials assessing fetuses with IUGR or oligohydram-
nios. Generalizability of the findings was limited. Thus,
adequately-powered, randomized controlled trials are still
needed to confirm these findings. Unfortunately, such trials
are costly but previous large observational studies often suf-
fer from important deficiencies in study design [5].
In a prospective, randomized trial, a woman would
receive either labor induction at certain gestational week or
expectant management to let the pregnancy continue in
the absence of pre-defined indications for delivery. How-
ever, previous retrospective studies have compared induced
with spontaneous labor at the same gestational week.
Critics of the retrospective studies point out that as the
pregnancy continues, certain risks accumulate. Randomized
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trials indicate, for instance, that induction at 41 weeks or
later reduces the risk of cesarean delivery [6]. On the other
hand, induction before 39 weeks may be associated with
suboptimal neonatal outcomes, and failed induction is not
uncommon particularly in nulliparas.
While awaiting large randomized trials to provide a
balanced, definitive answer, there may be opportunities
to use retrospective data to examine this issue with an
appropriate methodology. Despite that preventive induc-
tion of labor is commonplace in some institutions,
many women with the same non-urgent conditions are
managed expectantly. We reasoned that retrospectively
obtained data could be utilized to select pregnant
women who are clinically comparable, but among
whom one group received induction at a given gesta-
tional week (37–39 weeks) and the other continued the
pregnancy until later gestational weeks. These two
groups could then be used to compare the perinatal
outcomes. Thus, using data from the Consortium on
Safe Labor, a large, multicenter retrospective study, we
employed a propensity score analysis and intention-to-
treat principle to mimic a randomized clinical trial.
Our goal is to provide further evidence regarding
whether preventive induction of labor at 37–39 weeks
of gestation improves or adversely affects maternal and
neonatal outcomes.
Methods
Conceptual framework of the analysis
The objective of this study is to compare women who
had preventive induction of labor at a certain gestational
age with women who had similar characteristics and
conditions but were managed expectantly, i.e., their
pregnancies continued beyond that gestational age.
Figure 1 illustrates the conceptual framework. For ex-
ample, at 37 weeks of gestation, most women would
continue their pregnancies beyond 37 weeks. How-
ever, some would be delivered because of spontaneous
onset of labor, prelabor cesarean (elective or repeat),
or well-accepted clinical indications. Because such
subjects would be excluded from a randomized con-
trolled trial to test whether “preventive” labor
induction at 37 weeks of gestation improves perinatal
outcomes, we also excluded them from our analysis.
Among the remaining cohort of women at 37 weeks
gestation, those undergoing “preventive” induction of
labor for non-urgent indications would be the inter-
vention group and women continuing pregnancy
would be potential controls. Further selection criteria
are applied for final inclusion in the analysis (see below).
The same approach would be used to construct 38-week
and 39-week cohorts. These consecutive cohorts will
help to answer when is the best time to perform preventive
induction, if appropriate.
In our dataset, most women in the induction group
had non-urgent conditions of varying degrees of severity,
while the majority of expectant management group did
not. To select women who were likely to be qualified
candidates for preventive induction, we used propensity
score analysis to assign each woman a score based on
their characteristics and conditions [7, 8]. A high score
represents a high likelihood of preventive induction. In
the intervention group, most women had a high score
while the majority of expectant management group had
a low score. We then divided the intervention group into
four subgroups based on quartiles of the propensity
score in that group. We applied the same cut-off points
to the expectant management group (Fig. 1). Stratified
analyses based on the level of the propensity score were
conducted to compare maternal and neonatal outcomes
between the intervention and expectant management
groups at the corresponding level.
Study population
We used data from the Consortium on Safe Labor. Detailed
description of the study population is provided elsewhere
[9]. Briefly, the Consortium included 12 clinical centers
(with 19 hospitals) across 9 American Congress of Obstetri-
cians and Gynecologists (ACOG) districts. The study
included 228,562 deliveries with 233,730 newborns in
2002–2008; 87 % of the births occurred in 2005–2007. All
births at ≥23 weeks in these institutions were included. Par-
ticipating institutions extracted detailed information from
Fig. 1 A conceptual framework in selecting compatible subjects for
comparison. The intervention group (preventive induction) and
expectant management (ongoing pregnancies as control group) at a
particular gestational age (e.g., 37 weeks) were further divided based on
the propensity score for preventive induction. Propensity score levels are
divided based on the propensity scores in the preventive induction
group (<25th, 25th–49th, 50th–74th, and≥ 75th percentiles). These
cut-off points were then applied to the expectant management group.
1 = least likely to have preventive induction; 4 =most likely to have
preventive induction. Comparisons were made between the intervention
and control groups at the corresponding propensity score level
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their electronic medical records. Obstetric information was
linked to the newborn and neonatal intensive care unit
(NICU) records. Information on hospital and physician
characteristics was collected from surveys of the local
investigators. Maternal and newborn discharge summaries
(in ICD-9 codes) were linked to each delivery. Validation
studies indicated that the electronic medical records are
accurate representation of the medical charts in our study.
To avoid potential correlation between pregnancies of the
same individual, we selected only an individual’s first preg-
nancy in the study.
The Consortium on Safe Labor was approved by the
institutional review boards of the National Institutes of
Health, U.S.A. (IRB #2007-0656, date of approval 9/22/
2008) and all participating institutions. An individual
informed consent was not obtained because medical re-
cords were extracted without personal identification.
Analyzing the de-identified data for scientific publication
was exempted from IRB reviews.
Preventive Induction Group
For the preventive induction group, we first selected
subjects who had a singleton gestation, vertex presentation,
no uterine scar or fetal congenital anomalies, and were
delivered between 37 weeks +0 day and 39 weeks +6 days.
We excluded women who had spontaneous onset of labor,
premature rupture of the fetal membranes, placenta
previa, pre-labor cesarean section, clinically-indicated
induction or elective induction without any obstetric
indication, or antepartum complications (fetal distress,
chorioamnionitis, antepartum fetal death, thrombosis,
cerclage and active herpes).
In the current analysis, preventive induction is defined as
labor induction for any of the following reasons: hyperten-
sive disorders (gestational hypertension, chronic hyperten-
sion, unspecified hypertension excluding preeclampsia,
eclampsia and superimposed preeclampsia); maternal
medical problems (e.g., preexisting or gestational diabetes,
history of heart disease or renal disease); isolated oligohy-
dramnios or small-for-gestational-age; polyhydramnios; his-
tory of maternal or fetal conditions in prior pregnancy;
suspected macrosomia; vaginal bleeding in 3rd trimester
(but not immediately before labor).
Expectant management group
For the expectant management group, we selected subjects
who had a singleton gestation, vertex presentation, no uter-
ine scar or fetal congenital anomalies, and were delivered at
38 weeks +0 day or later. We excluded women who had
placenta previa or cerclage. Note that the expectant man-
agement group could be delivered by any method for any
reason after the “enrollment window”.
We then divided the induction group into five subsets
according to the time when preventive induction was
performed: 37+0–37+6, 38+0–38+3, 38+4–38+6, 39+0–39+3,
and 39+4–39+6 weeks. The corresponding expectant
groups were all eligible women who were delivered at ≥
38+0, ≥ 38+4, ≥ 39+0, ≥ 39+4 and ≥ 40+0 weeks, respect-
ively (Table 1). Thus, we had five cohorts with different
induction times.
Variable classification
We included a wide range of predictors (from maternal
demographic characteristics, underlying pregnancy com-
plications to physician and hospital characteristics) in the
propensity score model. A complete list of variables that
are included in the model is provided in the Appendix 1.
Our outcome measures include: cesarean delivery, mater-
nal and neonatal complications, admission to neonatal
intensive care unit, and duration of maternal hospital stay.
Since severe maternal and neonatal complications were
rare, we created maternal and neonatal composite indexes.
The maternal composite index includes maternal intensive
care unit admission, postpartum hemorrhage, postpartum
blood transfusion, shoulder dystocia, endometritis,
and 3rd or 4th degree perineal laceration. The neonatal
composite index includes stillbirth, birth injury, Apgar at
5 minutes < 4, neonatal sepsis, neonatal pneumonia,





Propensity score level* 1 2 3 4 1 2 3 4
Gestational age at
delivery
37+0–37+6 week ≥38+0 week
Nulliparas 128 129 128 129 50530 6785 3233 707




Nulliparas 175 176 175 176 39865 8098 3272 709




Nulliparas 85 85 85 85 42454 3774 1486 254




Nulliparas 251 252 251 252 21715 7690 1918 619




Nulliparas 52 53 52 53 21612 3178 1570 755
Multiparas 59 59 59 59 15437 3104 856 326
*Propensity score levels are divided based on the propensity scores in the
preventive induction group (<25th, 25th–49th, 50th–74th, and ≥ 75th
percentiles). These cut-off points were then applied to the expectant
management group
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intracranial hemorrhage, asphyxia, hemorrhagic-ischemic
encephalopathy, respiratory distress syndrome, neonatal
seizure, periventricular-intraventricular hemorrhage, nec-
rotizing enterocolitis, apnea, retinopathy of prematurity,
neonatal anemia, patent ductus arteriosis, ventilation,
blood transfusion, neonatal death, and pneumonia due to
aspiration or infection.
Data analysis
We first performed stratified analyses, comparing the in-
cidence of adverse outcomes between the induction and
expectant groups separated by the level of propensity
score, gestational age and parity. We then used a log
binomial model to produce relative risks of adverse
outcomes after adjusting for the propensity score [7].
A multiple linear regression was used to examine the
adjusted difference in duration of maternal hospital
stay. All analyses were performed using SAS 9.3.
Results
Table 1 presents the number of subjects under each cat-
egory. In the preventive induction group, the total number
of subjects was equally divided based on the quartile of
the propensity score in that group. When the same cut-off
points of the propensity score were applied to the expect-
ant group, the vast majority of the women had a low level
of propensity score.
Table 2 shows that in nulliparas, the rate of cesarean de-
livery increased with increasing propensity score. How-
ever, there was no difference in the composite maternal or
neonatal adverse outcomes overall, though some sporadic
differences were statistically significant. Similar findings
were observed among multiparas (Table 3). These analyses
indicate that the differences (or similarity) in the incidence
of adverse outcomes between the induction and expectant
groups did not vary substantially by the level of propensity
score and the gestational age at induction. Therefore, we
combined levels 3 and 4 of propensity score to increase
the statistical power.
Table 4 demonstrates that in both nulliparas and mul-
tiparas, preventive induction at 37 and 38 weeks was as-
sociated with a reduced risk of cesarean delivery comparing
to expectant management. No difference was observed at
39 weeks. However, at 37 weeks preventive induction was
associated with a two-fold increased risk of adverse neo-
natal outcomes and NICU admission in multiparas. The
Table 2 Preventive induction vs. expectant management in relation to maternal and perinatal outcomes in nulliparas
Gestational Propensity Cesarean delivery Maternal outcomes Neonatal outcomes NICU admission
Induction Expectant Induction Expectant Induction Expectant Induction ExpectantAge
(week)
Score
level (%) (%) P (%) (%) P (%) (%) P (%) (%) P
37+0–37+6 1 25.0 24.0 4.7 9.6 1.6 3.8 8.6 6.7
2 31.0 29.2 5.4 6.2 1.6 3.7 6.2 7.0
3 32.0 35.9 4.7 5.6 7.0 3.6 * 13.3 6.7 **
4 31.0 43.1 * 4.7 8.1 3.9 2.8 7.0 6.4
38+0–38+3 1 27.4 23.6 11.4 10.0 3.4 3.9 10.9 6.9 *
2 26.1 36.6 ** 8.5 6.9 3.4 3.3 9.1 6.9
3 24.0 25.6 12.0 5.1 *** 2.9 3.7 4.6 5.5
4 37.5 43.3 6.3 6.2 2.3 3.0 5.1 6.8
38+4–38+6 1 27.1 25.5 11.8 9.7 4.7 3.9 4.7 7.1
2 29.4 28.5 5.9 6.3 5.9 3.1 8.2 5.4
3 30.6 36.1 7.1 6.6 0.0 2.9 1.2 5.5
4 41.2 43.3 2.4 5.5 0.0 3.5 2.4 5.5
39+0–39+3 1 34.3 27.9 * 8.8 8.5 2.4 4.2 4.0 7.6 *
2 30.2 26.8 9.5 11.5 2.4 3.8 7.5 6.4
3 32.7 27.8 15.1 9.2 ** 3.2 4.0 5.2 7.0
4 34.9 38.8 11.1 10.2 2.0 4.5 6.0 7.6
39+4–39+6 1 17.3 27.9 15.4 10.3 3.8 4.4 5.8 7.9
2 39.6 31.8 11.3 5.8 0.0 3.5 1.9 4.8
3 38.5 28.3 5.8 7.3 1.9 3.6 3.8 5.6
4 32.1 37.2 11.3 4.6 * 3.8 2.9 5.7 6.6
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 3 Preventive induction vs. expectant management in relation to maternal and perinatal outcomes inmultiparas
Gestational Propensity Cesarean delivery Maternal outcomes Neonatal outcomes NICU admission
Induction Expectant Induction Expectant Induction Expectant Induction ExpectantAge
(week)
Score
level (%) (%) P (%) (%) P (%) (%) P (%) (%) P
37+0–37+6 1 8.3 5.5 9.5 7.3 3.0 2.0 7.7 4.0 *
2 4.1 7.6 7.6 4.4 * 3.5 2.0 10.0 4.0 ***
3 6.5 10.4 4.1 3.5 4.7 2.1 * 10.0 4.9 ***
4 4.7 15.5 *** 4.7 3.5 5.9 2.8 * 11.8 5.6 **
38+0–38+3 1 4.8 5.6 5.2 6.7 2.8 1.9 7.6 3.7 **
2 4.0 6.8 7.6 6.7 2.4 2.0 6.8 3.9 *
3 6.0 8.8 6.4 5.4 1.6 1.8 2.4 4.4
4 10.0 14.7 3.6 5.1 2.0 3.2 6.8 6.1
38+4–38+6 1 5.2 6.0 9.4 7.1 4.2 2.0 4.2 4.0
2 3.1 5.8 8.2 5.9 1.0 1.4 1.0 2.7
3 7.2 8.8 3.1 4.3 1.0 1.7 1.0 3.7
4 3.1 9.4 * 1.0 2.2 1.0 1.5 2.1 2.8
39+0–39+3 1 7.6 7.2 3.9 4.3 2.0 1.9 5.1 3.9
2 5.6 6.7 6.8 7.7 2.2 1.8 4.9 4.2
3 4.6 3.5 12.0 13.3 2.2 1.9 4.9 3.6
4 4.6 6.2 14.7 10.8 3.7 1.2 * 5.9 3.0 *
39+4–39+6 1 3.4 7.5 8.5 5.4 1.7 2.0 1.7 4.1
2 1.7 4.9 10.2 7.9 1.7 1.5 3.4 2.9
3 3.4 6.1 3.4 4.3 3.4 1.8 3.4 3.6
4 3.4 8.9 3.4 4.0 1.7 0.9 3.4 3.7
*p < 0.05; **p < 0.01; ***p < 0.001
Table 4 Adjusted relative risk of adverse outcomes by gestational age at intervention among women with a propensity score at
levels 3 and 4
Adverse outcome Gestational age at induction/delivery Nulliparas RR (95 % CI)a Multiparas RR (95 % CI)a
Cesarean delivery 37+0–37+6 vs. ≥ 38+0 0.80 (0.67–0.97) 0.42 (0.26–0.65)
38+0–38+6 vs. ≥ 39+0 0.83 (0.73–0.95) 0.65 (0.49–0.87)
39+0–39+6 vs. ≥ 40+0 0.95 (0.84–1.08) 0.96 (0.66–1.39)
Maternal adverse outcome 37+0–37+6 vs. ≥ 38+0 0.69 (0.39–1.23) 1.25 (0.73–2.14)
38+0–38+6 vs. ≥ 39+0 1.09 (0.76–1.55) 0.93 (0.63–1.36)
39+0–39+6 vs. ≥ 40+0 1.39 (1.07–1.81) 1.02 (0.82–1.26)
Neonatal adverse outcome 37+0–37+6 vs. ≥ 38+0 1.68 (0.97–2.92) 2.22 (1.32–3.74)
38+0–38+6 vs. ≥ 39+0 0.57 (0.30–1.10) 0.89 (0.49–1.63)
39+0–39+6 vs. ≥ 40+0 0.75 (0.44–1.26) 1.79 (1.08–2.98)
NICU admission 37+0–37+6 vs. ≥ 38+0 1.48 (0.99–2.20) 2.08 (1.47–2.96)
38+0–38+6 vs. ≥ 39+0 0.52 (0.32–0.84) 0.89 (0.60–1.34)
39+0–39+6 vs. ≥ 40+0 0.87 (0.61–1.24) 1.47 (1.02–2.12)
Mean difference (95 % CI, days)b Mean difference (95 % CI, days)b
Maternal hospital stay 37+0–37+6 vs. ≥ 38+0 1.07 (1.02–1.12) 1.13 (1.09–1.18)
38+0–38+6 vs. ≥ 39+0 1.04 (1.01–1.08) 1.06 (1.03–1.10)
39+0–39+6 vs. ≥ 40+0 1.07 (1.03–1.10) 1.11 (1.08–1.14)
alog binomial model adjusting for propensity score. bleast squares mean difference adjusting for propensity score
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trend appeared similar in nulliparas but less significant.
Women with preventive induction stayed in the hospital
significantly longer than women with expectant manage-
ment. Among women with a propensity score at levels 1
and 2, preventive induction was associated with an in-
creased risk of NICU admission at 37 and 38 weeks, and
had longer hospital stay. (Appendix 2).
Discussion
Our study was a multicenter, retrospective study. There
was no standard protocol for labor induction. Our data
reflected the current common practice of labor induc-
tion and cesarean delivery in the U.S. [9]Therefore, the
current study is more like an effectiveness trial (close to
reality) than an efficacy trial (more selective and strictly
controlled). We found that the major reduction in
cesarean rate was concentrated at early term (37–38
weeks). However, unintended consequences with regard
to unfavorable newborn outcomes were also observed at
37 weeks. The longer hospital stay for induced labor is
another factor to be taken into account. It remains to be
confirmed that a reduction in cesarean rate in this group
can compensate for the increased risk of adverse neo-
natal outcomes and longer hospital stay.
Is the effectiveness of preventive induction complication-
specific? The HYPITAT trial found that women with gesta-
tional hypertension or mild preeclampsia induced at 37–41
weeks’ gestation had a lower rate of cesarean section than
those received expectant monitoring [10]. A historical
cohort study suggested that more proactive post-term in-
duction was associated with improved perinatal outcomes
[11]. On the other hand, for women with uncomplicated
insulin-requiring diabetes, no significant difference in
cesarean rate was found [12]. Thus, it is possible that the
benefit of preventive induction may vary by type of compli-
cations. Unfortunately, due to the limited number of sub-
jects in our study, stratified analyses separated by each
complication were not possible.
Our finding that preventive induction at 37 weeks may
increase the risk of adverse neonatal outcomes is consist-
ent with the results from recent HYPITAT-II trial [13].
The latter study randomized 754 women to either planned
delivery at 34–36 weeks or expectant monitoring. It found
that while adverse maternal outcomes occurred in 0.9 %
and 2.8 % in the two groups, respectively, (RR = 0.30,
95 % CI 0.08–1.08), the incidence of neonatal respiratory
distress syndrome in the intervention group more than
doubled at late preterm.
It should also be noted that our study tried to mimic
a randomized clinical trial using propensity score
stratification and adjustment. This method of improv-
ing comparability has become more and more popular
in biomedical research [8]. Further, as we had included
a wide range of variables into this model, most
treatment-selection bias may have been eliminated
[14]. In addition, our study was able to separate by ges-
tational week and pinpoint where the benefits and
risks were.
The limitations of our study are also worth noting.
Due to the nature of the observational study, non-
documented factors that can influence the likelihood of
preventive induction of labor may not have been in-
cluded in the model. For instance, the status of the cer-
vix might have played a role in deciding whether to
perform preventive induction at early term or wait for
spontaneous onset of labor. If this is true, we may expect
to see that women who had preventive induction at early
term had a decreased risk of cesarean delivery than the
corresponding expectantly managed group due to more
favorable cervical status. Unfortunately, we don’t have
information on cervical ripeness at the time when the
decision of preventive induction was made. Likewise,
one may suspect that the increased risk of maternal and
neonatal adverse outcomes might have been due to
worse conditions leading to preventive induction, i.e.,
maternal and neonatal adverse outcomes were the
cause rather than the consequences. However, varia-
tions in the incidence of adverse maternal and neo-
natal outcomes by the propensity score were small,
suggesting that the potential bias introduced by the
cervical ripeness and maternal and fetal conditions
may not be substantial.
Another limitation of this study is its generalizability.
To have enough statistical power, we combined women
with various non-urgent medical conditions before
stratifying them by parity, gestational age and propensity
score. Women with the same score level had a compar-
able probability of preventive induction according to the
current standard of care, but their obstetrical risks might
be somewhat different because of different types of med-
ical conditions. And our study was not powerful enough
to analyze or discuss these factors individually. In sum-
mary, we found that preventive IOL for non-urgent indi-
cations may be associated with a decreased risk of
cesarean delivery at early term but increased risks of ad-
verse neonatal outcomes at 37 weeks. It also results in a
longer hospital stay than expectant management. In
order to develop a complete guidance on making clinical
decision, large randomized controlled trials for specific
obstetrical conditions such as gestational hypertension
or diabetes are still warranted.
Conclusions
Our study suggests that preventive induction for non-
urgent medical and obstetrical conditions at early term
(37–38 weeks of gestation) may be associated with a re-
duced risk of cesarean delivery. On the other hand,
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preventive induction at 37 weeks is associated with an
increased risk of adverse neonatal outcomes. Women
with induction stayed hospital longer than expectantly
managed women.
Appendix 1
Variables that were included in the propensity score model:
Maternal demographic characteristics
Maternal age, race, education level, height, weight at
admission to birth, marital status, insurance status;
Medical history
History of macrosomia, preterm and still births, preexisting
diabetes, chronic hypertension, heart, renal, gastrointes-
tinal, thyroid diseases, depression, seizure, use of assisted
reproductive technology;
Antepartum complications/conditions
Smoking, alcohol drinking, drug abuse during pregnancy,
hospitalization, sexually transmitted diseases, Group B
streptococcus, urinary tract infection, 3rd trimester vaginal
bleeding, anemia, asthma, hyper- or hypothyroidism,
gestational hypertension, chronic hypertension, unspecified
hypertension, gestational diabetes, threatened preterm
birth, incompetent cervix, suspected small-for-gestational-
age, suspected large-for-gestational-age, oligohydramnions,
polyhydramnios, placental abruption;
Hospital and delivering doctor’s characteristics
Sex and age of the physician, year of graduation, type of
physician practice, type of doctor’s malpractice insur-
ance, hospital type, hospital level, type of hospital insur-
ance, maternal-fetal medicine staff, hospitalist staffing,
use of midwife, neonatologist at delivery, NICU level,
use of epidural nurse, elective induction allowed, elective
cesarean delivery.
Table 5 Adjusted relative risk of adverse outcomes by gestational age at intervention among women with a propensity score at
levels 1 and 2
Adverse outcome Gestational age at induction/delivery Nulliparas RR (95 % CI)a Multiparas RR (95 % CI)a
Cesarean delivery 37+0–37+6 vs. ≥ 38+0 0.95 (0.78–1.15) 0.86 (0.57–1.30)
38+0–38+6 vs. ≥ 39+0 0.92 (0.80–1.07) 0.67 (0.47–0.96)
39+0–39+6 vs. ≥ 40+0 1.14 (1.01–1.29) 0.89 (0.69–1.16)
Maternal adverse outcome 37+0–37+6 vs. ≥ 38+0 0.79 (0.47–1.34) 1.66 (1.17–2.35)
38+0–38+6 vs. ≥ 39+0 1.41 (1.09–1.81) 1.01 (0.77–1.33)
39+0–39+6 vs. ≥ 40+0 1.07 (0.84–1.35) 0.86 (0.65–1.13)
Neonatal adverse outcome 37+0–37+6 vs. ≥ 38+0 0.41 (0.16–1.09) 1.69 (0.94–3.05)
38+0–38+6 vs. ≥ 39+0 1.10 (0.71–1.70) 1.32 (0.81–2.17)
39+0–39+6 vs. ≥ 40+0 0.53 (0.31–0.91) 1.01 (0.62–1.64)
NICU admission 37+0–37+6 vs. ≥ 38+0 1.08 (0.77–1.67) 2.27 (1.61–3.21)
38+0–38+6 vs. ≥ 39+0 1.50 (1.14–1.98) 1.61 (1.17–2.19)
39+0–39+6 vs. ≥ 40+0 0.74 (0.51–1.05) 1.27 (0.93–1.73)
Mean difference (95 % CI, days)b Mean difference (95 % CI, days)b
Maternal hospital stay 37+0–37+6 vs. ≥ 38+0 1.12 (1.07–1.18) 1.15 (1.10–1.21)
38+0–38+6 vs. ≥ 39+0 1.08 (1.04–1.12) 1.10 (1.06–1.14)
39+0–39+6 vs. ≥ 40+0 1.17 (1.13–1.20) 1.12 (1.08–1.16)
alog binomial model adjusting for propensity score. bleast squares mean difference adjusting for propensity score
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